Wall Street analyst estimates for Kyverna Therapeutics, Inc. (KYTX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 4 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.68 | ||
| 2026-08-12 | $-0.63 | $-0.68 | +7.1% |
| 2026-05-12 | $-0.66 | $-0.75 | +12.0% |
| 2026-03-26 | $-0.80 | $-0.84 | +5.3% |
| 2025-11-12 | $-0.85 | $-0.97 | +12.4% |
| 2025-08-12 | $-0.97 | $-1.00 | +3.0% |
| 2025-05-13 | $-1.03 | $-1.21 | +14.9% |
| 2025-03-27 | $-0.88 | $-0.87 | -1.1% |
Valuation Ratios
| Price / Book | 2.39 |
| EV / EBITDA | -2.96 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $5.7M | $7.0M | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | $1.7M | $2.1M | 0 |
| Gross Profit | $5.7M | $7.0M | -$1.7M | -$2.1M | 0 |
| Research & Development | $25.9M | $28.4M | $48.2M | $112.5M | $133.7M |
| Selling, General & Admin | $6.2M | $8.0M | $12.5M | $30.1M | $36.1M |
| Operating Expenses | $32.0M | $36.4M | $60.7M | $140.5M | $169.8M |
| Operating Income | -$26.3M | -$29.4M | -$62.4M | -$142.6M | -$169.8M |
| EBITDA | -$25.8M | -$27.8M | -$58.5M | -$125.2M | -$159.0M |
| Interest Expense | $3000 | $65000 | $187000 | $142000 | $489000 |
| Pre-tax Income | -$26.4M | -$28.9M | -$60.4M | -$127.5M | -$161.3M |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$26.4M | -$28.9M | -$60.4M | -$127.5M | -$161.3M |
| EPS | $-1.02 | $-1.12 | $-0.00 | $-3.33 | $-3.64 |
| EPS (Diluted) | $-1.02 | $-1.12 | $-0.00 | $-3.33 | $-3.64 |
| Shares Outstanding (Diluted) | $25.8M | $25.8M | $673.6M | $38.3M | $44.3M |
Price
| Price | $6.90 |
| Market Cap | $419M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ALLO · AVIR · CABA · CAPR · CTNM · EDIT · LXEO
Explore sector: Healthcare · Biotechnology
More sections of KYTX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks